Protected PCI

Patient Identification

Which Patients May Benefit from Protected PCI?

Impella® heart pumps may provide safe and effective hemodynamic support in elective and urgent high-risk PCI for a broad range of patients with complex coronary artery disease, hemodynamic compromise and comorbidities.

Use the Patient Selection Tool

Patients benefit from this minimally invasive option that may:

Enable more complete revascularization¹
Reduce symptoms and class of heart failure² and improve LVEF¹
Significantly reduce the overall incidence of post-procedural acute kidney injury (AKI)⁵
Reduce number of days in the hospital^3,4
Significantly reduce post-discharge MACCE events (composite of death/stroke/MI/repeat revascularization)⁶

Surgical Turndown is Common and Associated with Higher Mortality

Protected PCI may be an option when surgery is not. Consider Protected PCI for patients who are considered too high-risk and therefore turned down for surgery, and for patients who decline surgical treatment.

Is Your Patient a Candidate?

Underdiagnosed & Undertreated

Many patients with severe, symptomatic CAD remain untreated or undertreated due to comorbidities, increased risk of AKI or hemodynamic compromise.

Stay Up-to-Date

Resources from the Education Library

Protected PCI for Superior Long-Term Outcomes

Gregg Stone, MD, and Duane Pinto, MD, host this panel discussion from SCAI 2021 of Protected PCI and diagnosis and treatment of high-risk and complex coronary disease.

High-Risk PCI with Impella Support and Atherectomy

Thom Dahle, MD, presents the case of an 84-year-old with a history of CAD with prior stenting of the circumflex. In this case, the patient is his father.

Resources

Patient Selection Tool

Is your patient appropriate for Protected PCI? This patient selection tool is based on U.S. FDA safety and efficacy labeling, data from randomized control trials (RCTs), society guidelines and consensus documents.

Learn More

Protected PCI Coordinators

Learn how Protected PCI coordinators provide a vital service to heart teams that may result in new care pathways. Coordinators provide education and outreach for patients and referring physicians.

Learn More

Clinical Evidence

Read extensive data, including RCT findings and a published literature review of 3,301 patients, that supports Impella® safety and efficacy.

References

Burzotta, F., et al. (2019). J Interv Cardiol, 2019(5):1-10.
O’Neill, W.W., et al. (2012). Circulation, 126(14), 1717-1727.
Gregory, D., et al. (2013). Am Health Drug Benefits, 6(2), 88-99.
Maini, B., et al. (2014). Expert Rev Pharmacoecon Outcomes Res, 14(3), 403-416.
Flaherty, M.P., et al. (2017). Circ Res, 120(4), 692-700.
Dangas, G.D., et al. (2014). Am J Cardiol, 113(2), 222-228.

NPS-1180